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Abstract
The accumulation of neurofibrillary tangles in Alzheimer’s disease (AD) propagates with characteristic spatiotemporal
patterns which follow brain network connections, implying trans-synaptic transmission of tauopathy. Since misfolded
tau has been shown to transmit across synapses in AD animal models, we hypothesized that synapses in AD patients
may contain misfolded tau. By immunofluorescence imaging of bipartite synapses from AD subjects, we detected tau
protein in 38.4% of presynaptic and 50.9% of postsynaptic terminals. The pre/post distribution for hyperphosphorylated
tau was 26.9%/30.7%, and for misfolded tau 18.3%/19.3%. In the temporal cortex, microscopic aggregates of tau,
containing ultra-stable oligomers, were estimated to accumulate within trillions of synapses, outnumbering
macroscopic tau aggregates such as tangles by 10000 fold. Non-demented elderly also showed considerable
synaptic tau hyperphosphorylation and some misfolding, implicating the synapse as one of the first subcellular
compartments affected by tauopathy. Misfolding of tau protein appeared to occur in situ inside synaptic
terminals, without mislocalizing or mistrafficking. Misfolded tau at synapses may represent early signs of neuronal
degeneration, mediators of synaptotoxicity, and anatomical substrates for transmitting tauopathy, but its actual
role in these processes remain to be elucidated.
Introduction
The pathological hallmarks of Alzheimer’s disease (AD)
are senile plaques and neurofibrillary tangles (NFT) [1,2].
The accumulation of NFT, composed of misfolded, hyper-
phosphorylated tau proteins [3], follows a hierarchical
spatiotemporal pattern which is consistent with anatomical
connections in the brain [4,5]. It therefore appears that
NFT deposition spreads from one brain region to the next
along major axonal projections, but the underlying mech-
anism remains unclear. Given the ability of misfolded tau
to induce the misfolding of normal tau molecules via a
seeding mechanism [6-10], it has been hypothesized that
trans-synaptic transmission of misfolded tau molecules
m a yu n d e r l i et h es p r e a do ftauopathy [11-13], perhaps
analogous to the spread of prion proteins within the brain
[ 1 4 ] .S o m eh a v ep r o p o s e dt h a tm a n yn e u r o d e g e n e r a t i v e
disorders may share the general feature of “prion-like”
propagation of misfolded proteins [15,16].
Studies in animal models have demonstrated that
tauopathy can spread in the living brain, using either
transgenic mice that express mutant human tau proteins
specifically in the entorhinal cortex [11,17], or by inject-
ing tau aggregates into specific brain regions [18,19].
However, these processes are relatively inefficient, taking
weeks to months to observe, and occur only in situations
of high levels of exogenous or transgenic tau. Tau has
historically been identified as a microtubule-associated
protein localized to the axon of mature neurons [20,21],
and a prerequisite for trans-synaptic propagation would
be the localization of tau specifically at the synapse. We
therefore hypothesized that, for the propagation model to
be credible in human diseases, tau would need to be found
at the synapse (at least in the disease state); if present at the
synapse, the identification of tau species differentially
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pared to controls, will test the further hypotheses that
misfolded tau accumulates presynaptically before “release”
into postsynaptic space, and that tau is mislocalized to the
synapse in AD compared to normal neurons.
To test these hypotheses, we isolated and visualized
intact, bipartite human neuronal synapses from cortical
tissues of control and AD subjects. Using immunofluor-
escence to detect different forms of tau at bipartite
synapses, we found normal tau protein to be symmetric-
ally distributed across presynaptic and postsynaptic
terminals in the normal human brain. Misfolded tau in
AD-affected brains was also symmetrically distributed
on both sides of the synapse, forming sodium dodecyl
sulfate (SDS)-resistant oligomers. These data suggest
that synaptic tau becomes hyperphosphorylated and
misfolded in situ without significant spatial redistribu-
tion. Microscopic aggregates of misfolded tau deposited
within synapses may represent early signs of neuronal
degeneration, agents of synaptic toxicity, and anatomical
substrates responsible for the transmission of tauopathy.
Materials and methods
Reagents
Protease inhibitor (cOmplete tablet) was purchased from
Roche (Indianapolis, IN). Phosphatase inhibitor cocktails
2 and 3 were purchased from Sigma (St. Louis, MO) and
used in 1:1 combination. High-quality Triton X-100 (glass
ampule packaging) was purchased from Pierce (Rockford,
IL). Mouse monoclonal antibodies DA9 (total tau), PHF1
(pS396/pS404 tau), and Alz-50 (misfolded tau) were gifts
of Peter Davies (Albert Einstein College of Medicine). In
accordance with original studies of Alz-50 antibody [22],
we found Alz-50 to be weakly reactive against denatured
tau in Western blotting after SDS-PAGE. So Alz-50 is a
misfolded-conformation-specific tau antibody only under
non-denaturing conditions, suitable for immunostaining
of fixed cells/tissues.
Rabbit anti-tau (A20024) was purchased from Dako
(Glostrup, Denmark); Rabbit anti-PSD95 (#2507) from Cell
Signaling (Danvers, MA); Mouse anti-actin (A4700), rabbit
anti-actin (A5060), and mouse anti-MAP2 (M4403) from
Sigma; Mouse anti-synaptophysin (AB8049) from Abcam
( C a m b r i d g e ,M A ) ;R a b b i ta n t i - h i s t o n eH 3( 0 5 –928) from
Millipore (Billerica, MA); Mouse anti-GFAP (MS-1376)
from Thermo (Waltham, MA).
Human subjects
Brains from human subjects with a diagnosis of Alzheimer
disease or no cognitive deficits were obtained through the
Massachusetts Alzheimer’s Disease Research Center and
Massachusetts General Hospital Neuropathology Depart-
ment. All donor tissue was obtained in accord with local
and national IRB regulations. Characteristics of control and
AD subjects are listed in Table 1.
Subcellular fractionation and protein extraction
Frozen human cortical tissue was dissected to separate grey
matter from white matter, and 200–300 mg of thoroughly
thawed grey matter was gently ground in a Potter-Elvehjem
homogenizer with 1.5 mL ice-cold buffer A (25 mM
HEPES pH 7.5, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2,
2m MC a C l 2), supplemented with 2 mM DTT, protease
inhibitors and phosphatase inhibitors. The homogenate was
passed through two layers of 80 μm nylon filters (Millipore)
to remove tissue debris, and a 200 μLa l i q u o tw a ss a v e d .
The saved aliquot was mixed with 200 μL of water and
70 μL of 10% SDS, passed through a 27 gauge needle
several times to shear DNA, and boiled for 5 min to
prepare the total extract, followed by centrifugation at
15,000×g for 10 min to remove insoluble matter.
To prepare filtered synaptoneurosomes, the rest of the
homogenate was passed through a 5 μm Supor membrane
filter (PALL, Port Washington, NY) to remove large organ-
elles and nuclei, and centrifuged at 1,000×g for 5 min to
sediment synaptic terminals. Each pellet was resuspended
in buffer A, split into two aliquots, and centrifuged again to
yield two synaptoneurosome pellets. Supernatant from the
first centrifugation step was clarified by centrifugation at
100,000×g for 1 h to obtain the cytosol fraction. Cytosolic
extract was prepared by adding 1.5% SDS and boiling for
5 min. To prepare synaptoneurosome extracts, each synap-
toneurosome pellet was mixed with 250 μL buffer B
(50 mM Tris pH 7.5, 1.5% SDS, 2 mM DTT) and boiled for
5 min, followed by centrifugation at 15,000×g for 10 min to
remove insoluble matter. Synaptoneurosome pellets may be
snap frozen in liquid nitrogen and stored at −80°C.
Immunostaining of synaptoneurosomes
Four-well Lab-Tek II CC2 (polyamine pre-coated) chamber
slides (Nunc, Rochester, NY) were used for fixing and
imaging synaptoneurosomes. Each synaptoneurosome pel-
let was resuspended in 5 mL of ice-cold buffer C (10 mM
H E P E Sp H7 . 9 ,0 . 3Ms u c r o s e )b yg e n t l ep i p e t t i n g .U s i n ga
syringe with 27 gauge needle, 200 μL of synaptoneurosome
suspension (containing about 25 μg of total protein) was
transferred to each chamber well, followed by the addition
of 200 μL 2% paraformaldehyde in ice-cold PBS-MC
(phosphate buffered saline with 1 mM MgCl2 and 1 mM
CaCl2). After 10 min of incubation with 1% paraformalde-
hyde at 4°C, synaptoneurosomes became fixed and cross-
linked to the glass surface. Fixed synaptoneurosomes were
washed with PBS-MC (room temperature from this point
on) for three times (5 min each), and permeabilized for
10 min with 0.05% Triton X-100 in PBS-MC with 3%
bovine serum albumin (BSA, Sigma), followed by three
more washes. Slides were blocked with 4% normal goat
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and then incubated with primary antibodies diluted in
PBS-MC with 3% BSA for 90 min, followed by three
washes. Secondary antibodies diluted in PBS-MC with 3%
BSA were added for 50 min, followed by three washes.
The slide was mounted with #1.5 glass coverslip and
Prolong Gold Antifade reagent (Invitrogen, Carlsbad, CA).
Primary antibodies for immunostaining included guinea
pig anti-VGluT1 (Millipore AB5905, 1:150), chicken anti-
MAP2 (Abcam AB5392, 1:100), DA9 (mouse IgG, 1:150),
PHF1 (mouse IgG, 1:80), and Alz-50 (mouse IgM, 1:30).
Fluorescent secondary donkey antibodies were purchased
from Jackson Immunoresearch (West Grove, PA) and
used at 1:100 dilutions (anti-guinea pig DyLight 649, anti-
chicken Cy3, anti-mouse IgG Alexa 488, and anti-mouse
IgM Alexa 488).
Image acquisition and analysis
Immunofluorescence and brightfield images of synapto-
neurosomes were acquired on an AxioImager Z1 epifluor-
escence microscope (Carl Zeiss, Oberkochen, Germany)
equipped with a 63x oil immersion objective (N.A.= 1.40).
Images were deconvolved with the Iterative Deconvolution
plugin (by Bob Dougherty, OptiNav Inc.) in ImageJ soft-
ware (version 1.44). This 2D deconvolution program
required a point spread function (PSF) generated by
Diffraction Limit PSF plugin (Bob Dougherty, OptiNav
Inc.). For the brightfield image we used a 400 nm PSF;
for green fluorescence channel a 509 nm PSF; for red chan-
nel a 550 nm PSF; for far red channel a 650 nm PSF. The
optimal iteration number was empirically determined to be
12 for brightfield images and 16 for fluorescence images,
with the LP filter diameter set at 1.5 pixels. After deconvo-
lution, brightfield and fluorescence images were overlaid in
ImageJ (using hyperstacks) and protein colocalization was
determined by manual inspection. The cutoff threshold for
fluorescence signals (after deconvolution) was generally set
as two standard deviations above the mean. For stereologi-
cal counting, we created a 12×8 grid image which was over-
laid with microscope images, and devised a rule to
randomly select different grid areas to look for synaptic ter-
minals until the target number was reached. Two-way
ANOVA was computed using Graphpad Prism software
and t-tests were computed using Excel software.
Classification of synapse morphology
During stereological counting, we defined a synaptic
terminal as a brightfield object in the size range of
300–1000 nm with immunofluorescence signals for
either presynaptic (VGlut1) or postsynaptic (MAP2)
marker. Brightfield objects negative for both synaptic
markers were regarded as non-synaptic organelles/
vesicles, and these were not quantified, even if they were
positively stained by tau antibodies. To qualify as a
bipartite synapse, the brightfield object should show a
snowman-like structure or a non-spherical shape being
elongated or protruded, and pre/post makers needed
to be non-overlapping (judged by the centers of mass
of the puncta) and overlaid with the brightfield object
in a reasonable manner to be considered as adjacent
presynaptic and postsynaptic terminals. When synapses
were clustered together with other objects under the
brightfield, we did not attempt to classify them as bipartite
or hemi synapses. There were also tau-positive puncta
Table 1 Characteristics of control and AD subjects examined in this study
Case # Age (y) Gender Diagnosis Disease duration (y) ApoE genotype PMI (h) Braak stage
C1 76 F Control NA 3/3 24 1
C2 80 F Control NA 2/4 54 1
C3 76 M Control NA 3/4 48 1
C4 89 F Control NA 2/3 13 2
C5 91 F Control NA 3/3 19 2
C6 71 M Control NA NA 5 0
C7 87 M Control NA NA 36 1
A1 85 F AD 4 3/4 10 5
A2 73 F AD 19 3/3 14 5
A3 84 F AD 16 3/4 12 5
A4 92 M AD 22 4/4 12 5
A5 83 F AD 13 3/4 12 5
A6 82 M AD 6 3/4 7 6
A7 91 F AD 14 3/4 9 5
A8 95 M AD NA 3/3 11 6
NA= not applicable or not available; PMI = postmortem interval.
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were excluded from our analysis.
Transmission electron microscopy
Synaptoneurosome pellets were fixed in 2% glutaraldehyde
and 2% paraformaldehyde in PBS overnight at 4°C,
rinsed, post-fixed in 1% osmium tetroxide, and embed-
ded in LR White resin (Electron Microscopy Sciences,
Hatfield, PA) according to manufacturer’s protocols.
Embedded blocks were cut into 70-nm thin sections on an
Ultracut Microtome (Leica, Nussloch, Germany). Images
were acquired on a JEOL1011 transmission electron
microscope equipped with an ATM digital camera (JEOL
USA, Peabody, MA).
Gel electrophoresis and immunoblotting
SDS-denatured protein extracts were subjected to BCA
assay (Pierce) to determine protein concentrations. Extracts
were boiled again for 3 min after adding 5x sample buffer
(250 mM Tris pH 7.5, 5% SDS, 400 mM DTT, 50% gly-
cerol, 0.2% Orange G). Samples were resolved by SDS-
PAGE using Bis-Tris 4-12% precast gels (Invitrogen), and
transferred to low-fluorescence PVDF or nitrocellulose
membranes (Millipore) for immunoblotting, detected using
an Odyssey laser scanner (Li-Cor, Lincoln, NE). Blocking
buffer and fluorescent secondary antibodies were pur-
chased from Li-Cor and used according to manufacturer’s
protocols.
Results
Isolation and visualization of synaptic terminals from
postmortem tissues
We recently developed a method for isolating human syn-
aptic terminals from frozen (unfixed) postmortem brain
tissues, based on homogenization, 80 and 5 μmf i l t r a t i o n ,
and low-speed centrifugation (Figure 1A) [23]. The result-
ing subcellular fraction, called filtered synaptoneurosomes
[24], was enriched in synaptic marker proteins (synaptophy-
sin and PSD95) by immunoblotting (Figure 1B), and
enriched in synaptic structures under transmission electron
microscopy (Figure 1C, Additional file 1: Figure S1 and S2).
Using a gentle formaldehyde fixation protocol to crosslink
synaptoneurosomes onto polyamine-coated glass slides, we
could visualize individual synaptic or organelle structures
by brightfield microscopy (Figure 1D). Three channel
immunofluorescence was utilized to detect the presence
of tau (or its modified forms), the presynaptic marker
(vesicular glutamate transporter 1, VGluT1), and the
Figure 1 Isolation of human neuronal synapses for optical imaging. (A) Unfixed human brain tissue is homogenized, and synaptic terminals
are collected by subcellular fractionation. Synapse-enriched fractions, called synaptoneurosomes, are sparsely fixed over glass slides for optical imaging.
(B) Compared to total and cytosolic extracts, synaptoneurosomes (syn) analyzed by Western blotting show enrichment in presynaptic (synaptophysin)
and postsynaptic (PSD95) markers, and reduction in nuclear (histone H3) and astrocyte (GFAP) markers. Actin is a loading control. (C) Transmission
electron micrograph of synaptoneurosomes, with the arrow marking an intact synaptic cleft. (D) Light microscopy of synaptoneurosomes fixed over a
glass slide. Synapses and organelles appear as dark objects in brightfield images. Immunostaining against VGluT1 and MAP2 marks presynaptic and
postsynaptic terminals, respectively.
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MAP2).
A significant proportion of brightfield objects were
negative for synaptic markers (like object 2 in Figure 1D),
and by electron microscopy we observed non-synaptic
organelles such as mitochondria and myelin in the synap-
toneurosome preparation (Additional file 1: Figure S1).
Synaptophysin/PSD95 are commonly used pre/post-
synaptic markers, but we have previously observed that
their respective puncta often showed significant spatial
overlap [23], making it difficult to colocalize with a third
protein. So instead we chose the VGlut1/MAP2 marker
pair, which showed better puncta separation (see Figure 1D
for instance). Presynaptic marker VGlut1 is expected to
label the majority of glutamatergic presynaptic termi-
nals in the cortex [25], and we have previously shown
its usefulness for immunostaining human presynaptic
terminals in array tomography experiments [26]. Al-
though MAP2 is often used as a subcellular marker for
dendrites, its distribution in dendritic spines has been
clearly demonstrated by ultrastructural studies [27,28].
In the absence of interfering signals from dendrites,
we found it to be a useful marker for immunostaining
postsynaptic terminals [23].
The enrichment of MAP2 in both mouse and human
synaptoneurosomes was further demonstrated by im-
munoblotting with a different MAP2 antibody (mouse
monoclonal, Additional file 1: Figure S3), apart from
the chicken anti-MAP2 used for immunofluorescence.
Low molecular weight MAP2 (<100 kDa) appeared to
be more highly enriched in synaptoneurosomes than
common synaptic markers synatophysin and PSD95
(Figure 1B), confirming the synaptic localization of
MAP2. We have also tried phalloidin reagents to stain
postsynaptic terminals but they worked poorly (data
not shown) compared to anti-MAP2.
Biochemical and immunocytochemical detection of
synaptic tau misfolding
Since misfolded tau proteins are generally believed to be
seeds for transmitting proteinopathy [12,13], we tried to de-
tect their presence in synaptoneurosomes by two independ-
ent methods. The first method was SDS-polyacrylamide gel
electrophoresis (PAGE) analysis, followed by immunoblot-
ting (Figure 2A). In control cases, normal tau protein
migrated as a monomer around 60 kDa, being more
enriched in the cytosol (which included the axonal cyto-
plasm) than the synaptoneurosome, but with minimal
phosphorylation. AD cytosolic extracts similarly contained
mostly monomeric, non-phosphorylated tau. However, in
AD synaptoneurosomes, tau became hyperphosphorylated
and reactive against PHF1 antibody (pS396/pS404) [29],
and misfolded into SDS-resistant oligomers that migrated
as high molecular weight smears in the gel.
The second method utilized a conformation-specific anti-
body, Alz-50 [22], which recognized NFTs and dystrophic
neurites in AD-affected brains [30,31]. Immunostaining
against Alz-50 was strongly elevated in synaptoneurosomes
isolated from AD subjects compared to non-demented
controls (Figure 2B). By stereological counting, we detected
about 15% increase in Alz-50-positive terminals in AD sub-
jects over controls (Figure 2C). Altogether, our data showed
that tau underwent misfolding, hyperphosphorylation, and
oligomerization at AD-affected synapses.
Stereological counting in Figure 2C was conducted
over all synaptic terminals observable within chosen
areas, but it could be potentially confounded by the
uneven morphological distribution of synapses. So we
further classified observed synapses into three com-
mon morphology types, as shown in Figure 3. The first
morphology class was the intact, bipartite synapse, rep-
resented by snowman-like or elongated/protruded
structures under brightfield, with immunostaining for
VGluT1 and MAP2 on opposite sides. The second class
was the isolated hemi-synapse, represented by a single
object under brightfield, with immunostaining against
either VGluT1 or MAP2. These represented detached
presynaptic or postsynaptic (mushroom dendritic spine)
terminals. The third class had multiple synaptic or non-
synaptic structures clustered together (see Materials and
methods section for detailed classification criteria).
To better understand the spatial distribution of tau in
synaptic structures, we analyzed bipartite and hemi synap-
ses separately (Figures 4B and 5B), in addition to summing
over mixed morphologies (Figure 2C). In particular,
bipartite synapses allowed us to unambiguously assign
tau, or its phosphorylated or misfolded forms, into three
distribution patterns: presynaptic-only, postsynaptic-only,
or both sides.
Tau localizes to synapses to a similar extent in normal
aging and AD
In non-demented elderly, normal tau proteins were
detected by DA9 antibody at 76.0±2.9% (mean±S.E.M.) of
bipartite synapses, with a distribution ratio of 33.7%/37.5%/
4.8% (pre-only/post-only/both) (Figure 4). It was surprising
to find a slightly higher (not significant) fraction of postsyn-
aptic terminals containing tau compared to presynaptic
terminals, despite tau being concentrated in the axonal
cytoplasm of mature neurons [20,21].
We also examined isolated hemi-synapses from control
subjects, finding tau inside 67.2±2.3% of presynaptic
terminals and 71.9±2.1% of post synaptic terminals
(Figure 5). By multiplying these two numbers, we would
expect 44.0% of bipartite synapses to be tau-positive on
both sides, if they arose from random associations of hemi-
synapses. But the actual percentage of double-positive
bipartite synapses was much lower, only 4.8 ±1.8%, and the
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http://www.actaneurocomms.org/content/2/1/146Figure 2 Detection of misfolded tau in human synaptoneurosomes. (A) SDS-PAGE and Western blots of total (T), cytosolic (C), and
synaptoneurosomal (S) extracts show increases in hyperphosphorylated tau (detected by PHF1 antibody) and aggregated tau oligomers
(smears above 75 kDa) in AD-affected synaptoneurosomes compared to non-demented controls. Actin and PSD95 are markers to confirm
subcellular fractionation. (B) Using Alz-50 antibody to immunostain misfolded tau in synaptoneurosomes from control and AD subjects.
VGluT1 and MAP2 are presynaptic and postsynaptic markers, respectively. (C) Quantification of Alz-50 immunostaining in synaptoneurosomes
from control and AD subjects. Synaptic terminals of all morphologies were randomly counted based on stereology methods (3 controls, 300
presynapses, 195 postsynapses; 4 AD subjects, 400 presynapses, 320 postsynapses). Tau misfolding occurs more frequently in AD cases at both
presynaptic and postsynaptic sites (two-tailed t-test, **p < 0.01).
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Altogether, our results clearly established that tau was
abundantly distributed inside dendritic spines, in addition
to being axonal and presynaptic.
DA9 antibody could recognize both phosphorylated
and non-phosphorylated tau forms [32], and in AD sam-
ples 85.6 ±5.1% of bipartite synapses were tau (DA9)-
positive, with a distribution ratio of 34.6%:47.1%:3.8%
(pre-only/post-only/both) (Figure 4B). It revealed that
tau proteins did not mistraffic or mislocalize to synapses
in AD, since they were abundantly present in synapses
before AD.
Abnormal tau forms increase in AD-affected synapses
In bipartite synapses of AD subjects (Figure 4B), immuno-
staining with Alz-50 antibody detected misfolded tau at
both presynaptic and postsynaptic terminals, and the distri-
bution ratio was 15.4%:16.4%:2.9% (presynaptic-only/
postsynaptic-only/both), showing bilateral symmetry across
the synaptic cleft. As such, tau misfolding occurred at
34.6± 5.7% (mean± S.E.M.) of bipartite synapses from
the temporal lobe, a region marked by high NFT bur-
dens in AD [33]. The fraction containing hyperpho-
sphorylated tau was even higher at 53.8±4.7%, with
a distribution ratio of 23.1%:26.9%:3.8% (pre-only/post-
only/both). Tau hyperphosphorylation and misfolding were
significantly higher in AD compared to non-demented
c o n t r o l s( b yt w o - w a yA N O V A ,T a b l e2 ) .
By observing more frequent tau hyperphosphorylation
than misfolding in bipartite synapses (p<0.05, two-tailed
t-test, Figure 4B), our data supported the observation that
tau phosphorylation preceded fibril formation in the brain
and in cellular models [1,34,35]. The probability of tau
becoming hyperphosphorylated or misfolded was roughly
equivalent at presynaptic and postsynaptic sites. This was
also confirmed by counting hyperphosphorylated tau
(PHF1) and misfolded tau (Alz-50) in isolated hemi-
synapses from AD cases. The presynaptic:postsynaptic
ratios were 44.6%:46.6% (phospho) and 22.6%:32.8%
(misfolded), respectively (Figure 5B).
Comparing control and AD synaptoneurosomes
The percentage of synapses (bipartite and hemi) positive
for total tau was similar between control and AD subjects,
but abnormal forms of tau was elevated in the latter
(Figures 4B and 5B). However, appreciable amounts of
abnormal tau were detectable in control synaptoneuro-
somes, with hyperphosphorylation found in 20.9%:26.8%
(pre/post) and misfolding in 10.5%:13.7% (pre/post) of
hemi-synapses (Figure 5B). It appeared that tau abnormality
occurred at neocortical synapses in aging brains before
apparent AD pathology (Braak stages 1 or 2). AD would
Figure 3 Different morphologies of human synaptoneurosomes fixed over glass slides. Intact, bipartite synapses appear as snowman-like
or elongated/protruded structures under the brightfield, with VGluT1 (presynaptic marker) and MAP2 (postsynaptic marker) immunofluorescence
on opposing sides. Isolated hemi-synapses and clusters of synapses are more abundant than bipartite structures. The ratio of bipartite synapse/
hemi-synapse/clustered synapse is approximately 5%/50%/45%. Organelles negative for synaptic markers account for about half of the brightfield
objects, and these were excluded from our analysis of tau immunofluorescence.
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sphorylated and misfolded (Table 2), but the initial trigger
might have occurred in the preclinical stage of AD.
All forms of tau examined in this study, normal or
abnormal, generally showed similar frequencies on both
sides of bipartite synapses. This was true in both control
and AD subjects. Nor did we notice obvious intensity dif-
ferences between presynaptic and postsynaptic signals
after inspecting thousands of synaptic terminals, although
we did not formally quantify fluorescence signals. The
pre/post symmetry of tau distribution appeared to be an
invariant feature of normal and AD-affected brains.
Discussion
Misfolded tau oligomers deposited at synapses have the
potential to spread tauopathy
In this study, we detected misfolded tau in a significant
fraction of presynaptic and postsynaptic terminals in AD
subjects, which had two significant functional implica-
tions: (1) it could impair brain network function; (2) it
Figure 4 Tau localization in bipartite synapses. (A) Immunofluorescence detection by DA9 (total tau), PHF1 (pS396/pS404 tau), and Alz-50
(misfolded tau) in bipartite synapses, overlaid with brightfield (BF) images, from control and AD subjects. VGluT1/MAP2 are presynaptic/postsynaptic
markers. NA = not available. (B) Quantification of tau immunofluorescence in bipartite synapses. Bilaterally positive synapses for PHF1 and Alz-50 were
undetectable in control samples. 26 bipartite synapses per subject; 4 human subjects per group, except for control PHF1 and control Alz-50 experiments
which had only 3 subjects. Statistical results (n.s. not significant, *p < 0.05, **p < 0.01) are shown for two-way ANOVA (pre/post vs. Con/AD, black line) and
two-tailed t-test (red line).
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transmission.
The “transmission theory” of AD neurofibrillary path-
ology [12,13] predicts that there should be misfolded,
seeding-capable tau molecules localized inside synaptic
terminals. The true identity of tau species that seed intra-
cellular/trans-cellular tau aggregation remains unknown
in the human brain, but studies in cellular and animal
models have suggested that they may be oligomers or pro-
tofibrils [36-39]. Recently, Lasagna-Reeves et al. [18] have
immunopurified tau oligomers from AD brains that could
propagate tauopathy in living mice, and such oligomers
shared several similarities with synaptic tau oligomers
found in this study: (1) they migrated as smears between
Figure 5 Tau localization in hemi-synapses. (A) Immunofluorescence detection by DA9 (total tau), PHF1 (pS396/pS404 tau), and Alz-50 (misfolded
tau) in isolated hemi-synapses, overlaid with brightfield (BF) images, from control and AD subjects. VGluT1/MAP2 are presynaptic/postsynaptic markers.
(B) Quantification of tau immunofluorescence in scattered hemi-synapses. 51 hemi-synapses per subject; 4 human subjects per group, except for
control PHF1 and control Alz-50 experiments which had only 3 subjects. Statistical results (n.s. not significant, *p < 0.05, **p < 0.01) are shown for
two-way ANOVA (pre/post vs. Con/AD, black line; pre/post vs. PHF1/Alz-50, red line).
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amorphous aggregates instead of fibrillar.
Lasagna-Reeves et al. observed tau oligomers isolated
from AD brains forming amorphous globular aggregates
4–8 nm in diameter [18], while Maeda et al. also
reported granular tau oligomers from AD subjects in the
range of 5–50 nm [40]. Although we could not resolve
the size or number of microscopic aggregates within
each synaptic terminal by optical microscopy, under
electron microscopy we did not observe any fibril within
synaptic structures (Additional file 1: Figure S2). It was
likely that synaptic tau inclusions were also amorphous,
granular oligomers smaller than 50 nm, which appeared
to be the typical state of pre-fibrillar tau aggregates [41].
SDS-PAGE analysis showed that the core components of
these aggregates were ultra-stable oligomers. We also
observed that synaptic tau oligomers shared certain
conformational features (recognized by Alz-50 antibody)
with larger fibrillar inclusions like NFTs and neuropil
threads [22,30,31]. Hence, it is conceivable that the
former may be able to seed the formation of the latter.
Tau is present at synapses in sufficient quantities to
plausibly impact neural system function
The number of synapses and neurons in the human
temporal cortex has been estimated to be around 40 tril-
lion and 6 billion, respectively [42]. In temporal cortices of
end-stage AD subjects, we estimate that several trillion
synaptic terminals contain microscopic aggregates of
misfolded tau. On the other hand, the number of NFTs
was estimated to be a few hundred million in this brain re-
gion [33]. Given the extraordinary number of synapses
carrying misfolded tau, which may easily reach many bil-
lions in a tauopathy-affected area, the spread of misfolded
tau into interconnected brain regions may be quite appre-
ciable even if the probability of transmission is exceedingly
low, such as one millionth per day at each synapse.
Given the importance of synaptic plasticity in neural
transmission and memory encoding, the frequent depos-
ition of misfolded tau at synapses may contribute signifi-
cantly to cognitive decline in AD. This was supported by
our previous observation that tau oligomer levels, but not
Aβ oligomer levels, correlated with the disruption of the
ubiquitin-proteasome system at synapses [23]. Moreover, in
a special group of non-demented elderly with AD-like
neuropathology marked by high plaque and NFT burdens,
we observed that they did not develop synaptic tau oligo-
mers like AD subjects. In these cases, synaptic tau oligo-
mers appeared to be better correlated with dementia than
synaptic Aβ oligomers, NFTs, or plaques [43].
Synaptic compartments may exhibit early signs of
tauopathy
Although tau is highly enriched in axons as a microtubule
binding protein, its presence in other cellular compart-
ments such as somas, dendrites, and nuclei has been
clearly documented in healthy rodent and monkey brains
[44-46]. Tau also appears to interact with actin [47,48] and
various membranous structures within the neuron [49,50],
which may potentially explain its partitioning into post-
synaptic terminals instead of just presynaptic terminals.
With the progression of AD, misfolded tau accumulates in
the somatodendritic compartment [30,51], but we found
that the percentage of pre- and post-synaptic terminals
with total tau did not increase significantly with AD—only
phosphorylation and misfolding did. We found all forms
of tau to be symmetrically distributed across the synapse,
with or without AD. These data argue against the spatial
redistribution of synaptic tau molecules during AD patho-
genesis, but instead, tau hyperphosphorylation and
misfolding probably occurred in situ within each synaptic
terminal.
Inside individual terminals, hyperphosphorylation prob-
ably preceded misfolding, because more synapses showed
hyperphosphorylation than misfolding in AD brains. In
non-demented elderly, tau hyperphosphorylation was ob-
servation in ~20% of hemi-synapses (Figure 5B), which
may be an early sign of tau abnormality. We do not know
if this process began at a much younger age, or if it was
the result of abnormal tau being synaptically transmitted
from tangle-bearing regions. Most elderly over 65 would
be characterized as Braak Stage 1 or 2, with tangles
already present in the transentorhinal region [4,30].
Hyperphosphorylation is known to precede macro-
scopic tau aggregation during AD pathogenesis [1,30],
but the subcellular origin of tau abnormality remains
unclear. Our data suggest that one of the early signs of
tau abnormality may be hyperphosphorylation inside
Table 2 Summary of two-way ANOVA analyses of tau detection frequencies at bipartite synapses and hemi-synapses
Tau detection type Total tau Phosphorylated tau Misfolded tau
Synapse type Bipartite Hemi Bipartite Hemi Bipartite Hemi
P value Con vs. AD n.s. n.s. 0.0002 < 0.0001 0.0014 0.0004
(Con< AD) (Con<AD) (Con<AD) (Con< AD)
pre vs. post 0.0236 n.s. n.s. n.s. n.s. 0.0475
(pre<post) (pre< post)
n.s. = not significant.
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Hyperphosphorylated tau loses its ability to bind micro-
tubules [34,52,53], thereby gaining the tendency to
misfold.
Possible directionality in synaptic tau transmission
Recent studies using tauopathy mouse models have
shown that normal and misfolded tau both transmit
across brain regions via synaptic connectivity instead of
spatial proximity [11,17,19,54]. Moreover, both antero-
grade and retrograde spreading of tauopathy have been
observed along axonal tracts, suggesting that tauopathy
also transmits bidirectionally at synapses [19]. Our
data appear to be consistent with the possibility of
bidirectional transmission, since misfolded tau is equally
likely to be presynaptic or postsynaptic within a bipartite
synapse, but infrequently on both sides.
Recent studies have identified tau in secreted vesicles
of neuronal and non-neuronal cells [49,55], and in the
vesicle fraction of cerebrospinal fluids of early AD
patients [56]. Others have shown that membrane-free
tau aggregates added to culture media could also enter
neurons to induce further aggregation [36,37,39,57].
Hence, there are two possible routes for misfolded tau
to cross into another neuron via synaptic contacts,
which are illustrated in Figure 6.
The first pathway (Figure 6A) involves vesicular trans-
port between presynaptic and postsynaptic terminals [58].
Figure 6 Two plausible transmission mechanisms of misfolded tau across synapses. Having hyperphosphorylated tau (blue dots) and
misfolded tau (red dots) at opposing sides of the synapse may create an opportunity for spreading tauopathy. The infectious species, likely to be
oligomers (red irregular shapes), may either transmit by (A) vesicular trafficking, or (B) debris uptake. In (B), as tauopathy damages a neuron to
inflict neurite degeneration, tau oligomers may be incompletely degraded and remain as debris in the extracellular space. The neighboring
synaptic terminal may accidentally endocytose the debris containing tau oligomers, seeding further tau misfolding.
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suggests that either direction of transmission seems plaus-
ible. The second model (Figure 6B) is prompted by the
astronomical number of synaptic tau aggregates observed.
As a tauopathy-stricken neuron dies, what happens to the
hundreds of microscopic tau inclusions inside its synapses,
especially in distal neurites? Micro-aggregates containing
SDS-resistant tau oligomers are unlikely to be completely
removed by the proteolytic systems of a failing neuron.
Some aggregates may remain in its original place after the
neurite disintegrates, much like a ghost tangle that stands
in the place of a disintegrated neuron. It is conceivable
that oligomeric tau debris may be taken up by neighboring
neurites/synapses, causing tauopathy to spread in both
retrograde and anterograde directions.
Had we observed misfolded tau depositing at both
sides of the bipartite synapse with higher probability
than chance, it might have provided indirect evidence
for the vesicular transmission model in Figure 6A. This
was one of the original goals of our experimental design.
However, in our synaptoneurosome preparation, only a
few percent of bipartite synapses contained tau protein
on both sides, much lower than the expected value
(Figure 4B), and the underlying reason remains unclear.
Since well-characterized bipartite synapses were also rare
in our preparation, the sample number was too small for
estimating transmission probability. Further studies will
be required to provide supporting evidence for the
models proposed above.
Conclusion
In this study we developed a new procedure to image intact
synapses isolated from postmortem brain tissues and con-
ducted the first quantitative assessment of synaptic tauopa-
thy in AD. We demonstrated that tau misfolding occurs
symmetrically across the synapse with high frequencies of
oligomer deposition, revealing for the first time the extraor-
dinary number of synaptic terminals containing micro-
scopic tau inclusions. This methodology would be equally
applicable to other neurodegenerative tauopathies such as
progressive supranuclear palsy, certain forms of frontotem-
poral dementia, or corticobasal degeneration [59]. The
underlying reason that AD, but not other tauopathies
[51,60], shows a hierarchical pattern of NFT deposition
originating in transentorhinal regions still remains un-
answered. Comparing the synaptic distribution of tau and
analyzing its biochemical state in different tauopathies may
provide insights into their respective pathogenesis mecha-
nisms. The discovery of misfolded tau oligomers inside
synaptic terminals highlights novel targets for pathogenesis
studies and therapeutic interventions. For instance, tau
immunotherapy may be able to sequester extracellular mis-
folded tau after it escapes from pre- or post-synaptic com-
partments but before it enters another neuron. It remains
to be seen if synaptic deposition of misfolded proteins is a
common mechanism of neurodegenerative proteinopa-
thies, and imaging of isolated human synapses will be very
useful for such investigations.
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Additional file 1: Figure S1. Transmission electron micrographs of
human synaptoneurosomes isolated from non-demented controls, with
arrowheads marking the presence of (1) myelin fragment; (2) intact
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of synaptoneurosomes isolated from Alzheimer’s disease subjects. No visible
fibrils were observed. Figure S3: Immunoblotting with mouse anti-MAP2
and mouse anti-synaptophysin against total and synaptoneurosome (syn)
extracts from human controls and mouse brain tissues. Low molecular
weight MAP2 (<100 kDa) is highly enriched inside both human and mouse
neuronal synapses.
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